XORTX Therapeutics Files January 2025 6-K Report
Ticker: XRTX · Form: 6-K · Filed: Jan 21, 2025 · CIK: 1729214
Sentiment: neutral
Topics: reporting, regulatory-filing
TL;DR
XORTX files Jan 2025 6-K, confirms 20-F filing, CEO Davidoff signed off.
AI Summary
XORTX Therapeutics Inc. filed a Form 6-K on January 21, 2025, reporting for the month of January 2025. The filing was signed by CEO Allen Davidoff on January 17, 2025, indicating the company is a foreign private issuer and will file annual reports under Form 20-F. The company's principal business address is in Vancouver, Canada.
Why It Matters
This filing provides an update on XORTX Therapeutics' reporting status as a foreign private issuer, which can affect regulatory requirements and investor information accessibility.
Risk Assessment
Risk Level: low — This is a routine administrative filing confirming reporting status and not disclosing new material financial or operational information.
Key Players & Entities
- XORTX Therapeutics Inc. (company) — Registrant
- Allen Davidoff (person) — Chief Executive Officer
- January 2025 (date) — Reporting period
- January 17, 2025 (date) — Date of signature
- January 21, 2025 (date) — Filing date
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose is to report for the month of January 2025 and to indicate that XORTX Therapeutics Inc. is a foreign private issuer that files annual reports under Form 20-F.
Who signed this Form 6-K filing on behalf of XORTX Therapeutics Inc.?
Allen Davidoff, Chief Executive Officer, signed the Form 6-K filing.
On what date was this Form 6-K filed with the SEC?
This Form 6-K was filed with the SEC on January 21, 2025.
What is XORTX Therapeutics Inc.'s fiscal year end?
XORTX Therapeutics Inc.'s fiscal year end is December 31.
What is the Commission File Number for XORTX Therapeutics Inc.?
The Commission File Number for XORTX Therapeutics Inc. is 001-40858.
Filing Stats: 139 words · 1 min read · ~1 pages · Grade level 10.7 · Accepted 2025-01-21 10:24:54
Filing Documents
- f6k_012125.htm (6-K) — 4KB
- exh_991.htm (EX-99.1) — 4KB
- 0001171843-25-000338.txt ( ) — 9KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2025 Commission File Number: 001-40858 XORTX Therapeutics Inc. 3710 – 33rd Street NW, Calgary, Alberta, T2L 2M1 Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F [ X ] Form 40-F [ ] SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. XORTX Therapeutics Inc. (Registrant) Date: January 17, 2025 By: /s/ Allen Davidoff Name: Allen Davidoff Title: Chief Executive Officer EXHIBIT INDEX 99.1 News release dated January 17, 2025